Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.
Nadia Saoudi González1,2, Javier Ros1,2, Iosune Baraibar1,2
1Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Cancers
|January 23, 2024
Summary
Cetuximab, an EGFR-targeting antibody, offers personalized treatment for metastatic colorectal cancer (mCRC). It shows promise in combination therapies for specific molecular subgroups, improving outcomes for mCRC patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic colorectal cancer (mCRC) presents significant treatment challenges.
- Personalized medicine approaches are crucial for improving patient outcomes.
Purpose of the Study:
- To review the mechanism of action, characteristics, and indications of cetuximab in mCRC.
- To highlight cetuximab's role in novel combination therapies for specific mCRC molecular subgroups.
- To discuss the evolving landscape of cetuximab-based treatments for mCRC.
Main Methods:
- Literature review of cetuximab's efficacy and application in mCRC.
- Analysis of clinical trial data and molecular subgroup targeting.
- Synthesis of information on cetuximab's role in combination therapies.
Main Results:
- Cetuximab is an effective EGFR-targeting monoclonal antibody for mCRC.
- It demonstrates efficacy in specific molecular subgroups, including BRAF V600E, KRAS G12C, and HER2-altered mCRC.
- Combination therapies involving cetuximab show potential in overcoming treatment resistance.
Conclusions:
- Cetuximab is a cornerstone of personalized targeted therapy for mCRC.
- Its strategic use in combination with other agents expands therapeutic options and offers hope for resistant cases.
- Ongoing research continues to refine cetuximab-based treatment strategies for mCRC.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K